Original title: Reduction in Cardiac Mortality with Bivalirudin in Patients With and Without Major Bleeding: The HORIZONS-AMI Trial. Reference: Gregg W. Stone et al. J Am Coll Cardiol. Epub ahead of print The HORIZONS -AMI study included 3602 patients experiencing ST segment elevation myocardial infarction received primary angioplasty, resulting in lower mortality at 30 days and three years<a href="https://solaci.org/en/2013/10/21/low-cardiac-mortality-with-bivalirudin-beyond-the-reduction-in-major-bleeding/" title="Read more" >...</a>
Infarct size reduction to 30 days could result in clinical benefit at one year
Original title: Intralesional abciximab and thrombus aspiration in patients with large anterior myocardial infarction: One-year results from the INFUSE-AMI trial. Reference: Stone GW et al. Circ Cardiovasc Interv. 2013;Epub ahead of print. The intra-coronary infusion of Abciximab added to thromboaspiration seems to improve outcomes at one year in patients undergoing primary angioplasty for ST-segment elevation with anterior<a href="https://solaci.org/en/2013/10/16/infarct-size-reduction-to-30-days-could-result-in-clinical-benefit-at-one-year/" title="Read more" >...</a>
The radial approach for PCI reduces mortality
Original title: Radial Versus Femoral Access for Primary Percutaneous Interventions in ST-Segment Elevation Myocardial Infarction Patients. A Meta-Analysis of Randomized Controlled Trials. Reference: Wassef Karrowni et al. J Am Coll Cardiol Intv 2013;6:814–23. Bleeding is the most frequent in-hospital complication of PCI, and it is clearly associated with adverse events that include death. STEMI patients require emergency<a href="https://solaci.org/en/2013/10/02/the-radial-approach-for-pci-reduces-mortality/" title="Read more" >...</a>
Ticagrelor effective in venous bridges
Original title: Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass grafo surgery: Inssights from th PLATelet inhibition and patients outcomes (PLATO) trial. Reference: Emmanouil S. Brilakis, et al. Am Heart J 2013;166:474-80 The bridge venous occlusion is a common finding in patients with previous CABG presenting with acute coronary syndrome without ST<a href="https://solaci.org/en/2013/09/27/ticagrelor-effective-in-venous-bridges/" title="Read more" >...</a>
Paclitaxel eluting balloon . More effective in restenosis of BMS than DES
Original title: A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Referencia: Seiji Habara et al. Am Heart J 2013;166:527-533.e2. Paclitaxel – eluting balloons have recently emerged as an option for treating in-stent restenosis, both conventional stents ( BMS ) and with drugs (DES ).<a href="https://solaci.org/en/2013/09/25/paclitaxel-eluting-balloon-more-effective-in-restenosis-of-bms-than-des/" title="Read more" >...</a>
Usefulness of FFR in coronary bypass intermediate lesions
Original title: Long-term clinical outcome after fractional flow reserve– versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. Reference: Luigi Di Serafino et al. Am Heart J 2013;166:110-8. Bypass coronary angioplasty is often preferred strategy versus re-operation , however it is associated with a greater number of events, both short and long<a href="https://solaci.org/en/2013/09/24/usefulness-of-ffr-in-coronary-bypass-intermediate-lesions/" title="Read more" >...</a>
Everolimus Eluting Stent in multiple vessels with short SYNTAX score
Original title: A Clinical and Angiographic Study of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With Multivessel Coronary Artery Disease. The EXECUTIVE (EXecutive RCT: Evaluating XIENCE V in a Multi Vessel Disease) Trial. Reference: Flavio Ribichini et al. J Am Coll Cardiol Intv 2013. Article in press. Drug-eluting stents (DES ) have emerged<a href="https://solaci.org/en/2013/09/24/everolimus-eluting-stent-in-multiple-vessels-with-short-syntax-score/" title="Read more" >...</a>
Difference in mortality with surgery versus angioplasty in diabetic multivessel patients
Original title: Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: A meta-analysis of randomized controlled trials. Reference: Verma S. et al. Lancet Diabetes Endocrinol. 2013;Epub ahead of print. The FREEDOM study was the last of the randomized studies that compared the results of surgery versus coronary angioplasty in diabetic multivessel patients showing a<a href="https://solaci.org/en/2013/09/18/difference-in-mortality-with-surgery-versus-angioplasty-in-diabetic-multivessel-patients/" title="Read more" >...</a>
Enoxaparin appears superior to unfractionated heparin in patients undergoing primary angioplasty
Original title: A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). Reference: Collet et al. Am J Cardiol. 2013; Epub ahead of print. ATOLL study analysis suggests that enoxaparin is superior to unfractionated heparin in reducing ischemic events and mortality in patients suffering ST elevation acute myocardial infarction (STEMI)<a href="https://solaci.org/en/2013/09/16/enoxaparin-appears-superior-to-unfractionated-heparin-in-patients-undergoing-primary-angioplasty/" title="Read more" >...</a>
Thromboaspiration in AMI, without benefit to 30 days.
Original title: Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. TASTE trial. Reference: Ole Fröbert et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1308789 One of the biggest challenges of primary angioplasty is to restore normal coronary flow. Thromboaspiration is a relatively simple, quick and cheap it can improve the flow and resolution of ST , however , the<a href="https://solaci.org/en/2013/09/11/thromboaspiration-in-ami-without-benefit-to-30-days/" title="Read more" >...</a>